MTOR and tuberous sclerosis: Emerging evidence suggests that epigenetic mechanisms, including DNA methylation and miRNAs, may offer therapeutic potential in TSC by modulating critical pathological pathways such as inflammation, tumorigenesis, and mTOR signaling.